{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:13:05Z","timestamp":1771945985673,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ad.2012.06.018","type":"journal-article","created":{"date-parts":[[2012,11,9]],"date-time":"2012-11-09T21:22:39Z","timestamp":1352496159000},"page":"122-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bases inmunol\u00f3gicas de la hipopigmentaci\u00f3n vitiligoide asociada a melanoma"],"prefix":"10.1016","volume":"105","author":[{"given":"R.","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Torres-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2012.06.018_bib0005","series-title":"Fitzpatrick: Dermatolog\u00eda en medicina general","first-page":"938","article-title":"Cap. 90 Hipomelanosis e hipermelanosis","author":"Ortonne","year":"2005"},{"key":"10.1016\/j.ad.2012.06.018_bib0010","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1365-4632.2004.02468.x","article-title":"Regressing cutaneous malignant melanoma and vitiligo-like depigmentation","volume":"45","author":"Arpaia","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2012.06.018_bib0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1196\/annals.1423.043","article-title":"Harnessing autoimmunity (vitiligo) to treat melanoma: A myth or reality?","volume":"1110","author":"Ram","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ad.2012.06.018_bib0020","series-title":"Fitzpatrick: Dermatolog\u00eda en medicina general","first-page":"1029","article-title":"Cap. 93. Neoplasias: melanoma cut\u00e1neo","author":"Langley","year":"2005"},{"key":"10.1016\/j.ad.2012.06.018_bib0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ad.2012.06.018_bib0030","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC Melanoma Staging and Classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2012.06.018_bib0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.clim.2008.02.011","article-title":"Focus on FOCIS: Interleukin 2 treatment associated autoimmunity","volume":"127","author":"Moschos","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ad.2012.06.018_bib0040","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1038\/sj.onc.1206462","article-title":"Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity","volume":"22","author":"Ram\u00edrez-Montagut","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ad.2012.06.018_bib0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/jid.2009.334","article-title":"KIT as a therapeutic target in melanoma","volume":"130","author":"Garrido","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2012.06.018_bib0050","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ad.2012.06.018_bib0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ad.2012.06.018_bib0060","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00262-010-0942-x","article-title":"Wild-type and modified gp-100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used","volume":"60","author":"Lesterhuis","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ad.2012.06.018_bib0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20091918","article-title":"Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts","volume":"207","author":"Quezada","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.ad.2012.06.018_bib0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1346-8138.2006.00235.x","article-title":"Vitiligo associated with malignant melanoma and lupus erythematosus","volume":"34","author":"G\u00fcl","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2012.06.018_bib0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ad.2012.06.018_bib0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2230.2008.02872.x","article-title":"Metastatic malignant melanoma associated with vitiligo-like depigmentation","volume":"34","author":"Wang","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2012.06.018_bib0085","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s12032-011-0146-z","article-title":"Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?","volume":"29","author":"Salas-Alan\u00eds","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.ad.2012.06.018_bib0090","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1468-3083.2006.01628.x","article-title":"Vitiligo-like depigmentation as a presenting sign of metastatic melanoma","volume":"20","author":"Kiecker","year":"2006","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.ad.2012.06.018_bib0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0001-7310(03)76666-6","article-title":"Leucodermia en pacientes con melanoma tratados con interfer\u00f3n","volume":"94","author":"Garc\u00eda-F-Vilalta","year":"2003","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2012.06.018_bib0100","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1610-0387.2008.06755.x","article-title":"Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features","volume":"6","author":"Hartmann","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2012.06.018_bib0105","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/000155598442944","article-title":"On the association between vitiligo and malignant melanoma","volume":"78","author":"Lindelof","year":"1998","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2012.06.018_bib0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02737633","article-title":"The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions","volume":"16","author":"Merimsky","year":"1998","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ad.2012.06.018_bib0115","first-page":"798","article-title":"Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radiobinding assay","volume":"139","author":"Kemp","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ad.2012.06.018_bib0120","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","article-title":"Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma","volume":"126","author":"Boasberg","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2012.06.018_bib0125","first-page":"74","article-title":"Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod","volume":"33","author":"Mashia","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2012.06.018_bib0130","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0749.2005.00244.x","article-title":"Melanocyte-specific, cytotoxic T cells responses in vitiligo: the effective variant of melanoma immunity?","volume":"18","author":"Garbelli","year":"2005","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.ad.2012.06.018_bib0135","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/0008-5472.CAN-03-2828","article-title":"Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells","volume":"64","author":"Lengagne","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ad.2012.06.018_bib0140","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI44849","article-title":"Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma","volume":"121","author":"Byrne","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ad.2012.06.018_bib0145","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocytes-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ad.2012.06.018_bib0150","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1200\/JCO.2008.17.3161","article-title":"Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens","volume":"26","author":"Slingluff","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731012004413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731012004413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:00:55Z","timestamp":1757552455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731012004413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0001731012004413"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2012.06.018","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bases inmunol\u00f3gicas de la hipopigmentaci\u00f3n vitiligoide asociada a melanoma","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2012.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Espa\u00f1a, S.L. and AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}